Shimla Online

Stargardt Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

 Breaking News
  • No posts were found

Stargardt Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

March 16
17:30 2020
Stargardt Disease Market Insight, Market Size, Epidemiology, Leading Companies, Emerging and Marketed Therapies By DelveInsight

Stargardt Disease Market Insight Report
DelveInsight’s “Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Albany, US – DelveInsight has launched a new report on Stargardt Disease Market Insights, Epidemiology and Market Forecast-2030  

The Stargardt Disease market report provides current treatment practices, emerging drugs, Stargardt Disease market share of the individual therapies, current and forecasted Stargardt Disease Pain market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Stargardt Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

Key benefits of the report
1. Stargardt Disease market report covers a descriptive overview and comprehensive insight of the Stargardt Disease epidemiology and Stargardt Disease market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) 
2. Stargardt Disease market report provides insights on the current and emerging therapies.
3. Stargardt Disease market report provides a global historical and forecasted market covering drug outreach in 7 MM.   
4. Stargardt Disease market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Stargardt Disease market.

           

 Request for sample pages here -> https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market

“Stargardt disease is the most common form of inherited macular degeneration, affecting about 30,000 people in the U.S.”

The disease has an autosomal recessive inheritance associated with disease-causing mutations in the ABCA4 gene.
There are no approved Stargardt disease treatments available, and other therapeutic approaches do not target its root cause.

There are three main modes of the intervention being explored, with human clinical trials of stem cell therapy, gene replacement therapy and pharmacological approaches.

Stargardt disease does not have a treatment yet. It is sometimes treated with intraocular injections of anti-VEGF drugs.

The diagnosis, prognosis, and management of Stargardt disease continue to be challenging in current practice. This is related to an incomplete understanding of the pathophysiology of the disease process, complexity of initiating factors and lack of safe and effective therapies for low-risk Stargardt disease affected individuals.

To summarize, a better and clear understanding of the pathogenesis will significantly improve the Stargardt disease treatment regimens and development of novel therapies. With this, several companies have started working towards the development of new therapeutic options. Stargardt disease market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the expected launch of distinctive emerging therapies in the coming years.

The other factors that shall further fuel the growth of Stargardt disease market include increased understanding about the disease, introduction of novel therapies in Stargardt disease market and need for curative therapy. These all will contribute towards the Stargardt disease market growth during the forecast period (2020–2030).

Drugs covered
1. ALK-001
2. Emixustat
3. ASP7317
And many others

The key players in Stargardt Disease market are:
1. Alkeus Pharmaceuticals
2. Acucela Pharmaceuticals
3. Astellas Pharma
And many others

Table of contents
1. Report Introduction
2. Stargardt Disease Market Overview at a Glance
3. Stargardt Disease Disease Background and Overview
4. Stargardt Disease Epidemiology and Patient Population
5. Stargardt Disease Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1. Germany
5.2.2. France
5.2.3. Italy
5.2.4. Spain
5.2.5. United Kingdom
5.3. Japan
6. Stargardt Disease Treatment & Medical Practices
7. Stargardt Disease Emerging Therapies
7.1. Key Cross Competition
7.2. ALK-001 : Alkeus Pharmaceuticals
7.3. Emixustat: Acucela Pharmaceuticals
7.4. ASP7317: Astellas Pharma
8. Stargardt Disease Market Size
8.1. Key Findings
8.2. Total 7MM Stargardt Disease Market Analysis
9. 7MM Stargardt Disease Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Market Drivers
11. Market Barriers
12. Stargardt Disease Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight

Request for sample pages here -> https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market

 

Related Reports:

DelveInsight’s ‘Stargardt Disease (STGD) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Stargardt Disease (STGD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Stargardt Disease (STGD) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Stargardt Disease (STGD) market. A detailed picture of the Stargardt Disease (STGD) pipeline landscape is provided, which includes the disease overview and Stargardt Disease (STGD) treatment guidelines. The assessment part of the report embraces in-depth Stargardt Disease (STGD) commercial assessment and clinical assessment of the Stargardt Disease (STGD) pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Stargardt Disease (STGD) collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Priya Maurya
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Related Articles